Literature DB >> 26703097

The Role of Cholesterol in the Pathogenesis of NASH.

George N Ioannou1.   

Abstract

Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellular carcinoma (HCC). While the underlying molecular mechanisms responsible for the development of inflammation and fibrosis that characterize progressive NASH remain unclear, emerging evidence now suggests that hepatic free cholesterol (FC) is a major lipotoxic molecule critical in the development of experimental and human NASH. In this review, we examine the effects of excess FC in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and the subcellular mechanisms by which excess FC can induce cellular toxicity or proinflammatory and profibrotic effects in these cells. Published by Elsevier Ltd.

Entities:  

Keywords:  NAFLD; NASH; cholesterol crystals; fibrosis; inflammation

Mesh:

Substances:

Year:  2015        PMID: 26703097     DOI: 10.1016/j.tem.2015.11.008

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  128 in total

1.  Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.

Authors:  George N Ioannou; Savitha Subramanian; Alan Chait; W Geoffrey Haigh; Matthew M Yeh; Geoffrey C Farrell; Sum P Lee; Christopher Savard
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

2.  Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.

Authors:  Sofia de Oliveira; Ruth A Houseright; Alyssa L Graves; Netta Golenberg; Benjamin G Korte; Veronika Miskolci; Anna Huttenlocher
Journal:  J Hepatol       Date:  2018-12-18       Impact factor: 25.083

3.  Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution.

Authors:  Joel T Haas; Luisa Vonghia; Denis A Mogilenko; An Verrijken; Olivier Molendi-Coste; Sébastien Fleury; Audrey Deprince; Artemii Nikitin; Eloïse Woitrain; Lucie Ducrocq-Geoffroy; Samuel Pic; Bruno Derudas; Hélène Dehondt; Céline Gheeraert; Luc Van Gaal; Ann Driessen; Philippe Lefebvre; Bart Staels; Sven Francque; David Dombrowicz
Journal:  Nat Metab       Date:  2019-06-14

4.  Cranberry (Vaccinium macrocarpon) extract treatment improves triglyceridemia, liver cholesterol, liver steatosis, oxidative damage and corticosteronemia in rats rendered obese by high fat diet.

Authors:  Thamara C Peixoto; Egberto G Moura; Elaine de Oliveira; Patrícia N Soares; Deysla S Guarda; Dayse N Bernardino; Xu Xue Ai; Vanessa da S T Rodrigues; Gabriela Rodrigues de Souza; Antonio Jorge Ribeiro da Silva; Mariana S Figueiredo; Alex C Manhães; Patrícia C Lisboa
Journal:  Eur J Nutr       Date:  2017-05-13       Impact factor: 5.614

5.  Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

Authors:  Xiaobo Wang; Ze Zheng; Jorge Matias Caviglia; Kathleen E Corey; Tina M Herfel; Bishuang Cai; Ricard Masia; Raymond T Chung; Jay H Lefkowitch; Robert F Schwabe; Ira Tabas
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

6.  Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol.

Authors:  Janin Henkel; Charles Dominic Coleman; Anne Schraplau; Korinna Jӧhrens; Daniela Weber; José Pedro Castro; Martin Hugo; Tim Julius Schulz; Stephanie Krämer; Annette Schürmann; Gerhard Paul Püschel
Journal:  Mol Med       Date:  2017-03-21       Impact factor: 6.354

7.  Mice lacking ARV1 have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease.

Authors:  Christina Gallo-Ebert; Jamie Francisco; Hsing-Yin Liu; Riley Draper; Kinnari Modi; Michael D Hayward; Beverly K Jones; Olesia Buiakova; Virginia McDonough; Joseph T Nickels
Journal:  J Biol Chem       Date:  2018-02-28       Impact factor: 5.157

8.  E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver.

Authors:  Qiuwen Lai; Albert Giralt; Cédric Le May; Lianjun Zhang; Bertrand Cariou; Pierre-Damien Denechaud; Lluis Fajas
Journal:  JCI Insight       Date:  2017-05-18

9.  Screening of non-alcoholic steatohepatitis (NASH)-related datasets and identification of NASH-related genes.

Authors:  Ming-Jiang Liu; Hu Jin; Yu-Bing Chen; Jing-Jing Yu; Zhen-Ya Guo; Song-Qing He; Yong-Lian Zeng
Journal:  Int J Clin Exp Pathol       Date:  2021-05-15

Review 10.  Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?

Authors:  Mark A Febbraio; Saskia Reibe; Shabnam Shalapour; Geraldine J Ooi; Matthew J Watt; Michael Karin
Journal:  Cell Metab       Date:  2018-11-15       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.